AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02616731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diosmin
Description: use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
Study NCT00229593 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testosterone Gel
Description: 100 mg Testosterone gel daily for 3 weeks
Study NCT00969696 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8Mg a day of a sugar pill
Study NCT00969696 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Galantamine
Description: 8mg of Galantamine
Study NCT01216631 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: intra-articular injection of methylprednisolone (80mg given at baseline only)
Study NCT01216631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: intra-articular injection of 100mg infliximab given at baseline only
Study NCT01216631 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Infliximab
Description: intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
Study NCT02747290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-BBN-RGD
Description: 68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
Study NCT01942343 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration
Study NCT01809106 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: 60 mg /24 ore
Study NCT01809106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: 25 microg/h
Study NCT01809106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: 35 microg/h
Study NCT01809106 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: 40 mg /24 ore
Study NCT01890070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hazelnuts
Description: Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
Study NCT05451225 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Targeted Educational Campaign
Description: Correction Officers will be exposed to the Targeted Educational Campaign (TEC) with the aim to increase their knowledge about the early symptoms of psychosis, and how to make a referral to the Correction Health Services staff, their self-efficacy to detect symptoms of psychosis and make referrals, and their expectations about their ability to be successful in making that referral (and for referrals to result in beneficial outcomes).~Correction Officers will be approached and recruited during roll call and in the staff canteen where they take their meal breaks, or at a time/location agreed upon by the Department of Correction, to complete brief surveys at three different times; pre-exposure, after 6 months, and after 12 months from the beginning of the TEC.
Study NCT05123170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Injectable Solution [Dexdomitor]
Description: two different doses of dexemedetomidine (0.25 μg /kg and 0.5 μg/kg) as adjunct to lignocaine in intravenous regional anesthesia for upper limb orthopedic surgeries
Study NCT05123170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine IV
Description: Intravenous regional anaesthesia
Study NCT03833661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M7824
Description: Participants received an intravenous infusion of 1200 milligrams (mg) M7824 once every 2 weeks until confirmed disease progression, death, unacceptable toxicity or study withdrawal.
Study NCT01890070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
Study NCT01890070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Red wine
Description: Italian Organic Red Wine
Study NCT01890070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Oil
Description: Italian Organic Olive Oil
Study NCT01890070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild mixed greens
Description: Italian organic wild mixed greens
Study NCT01570348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO
Study NCT04630535 — intervention group
Intervention type: PROCEDURE
Intervention: aorto-bifemoral bypass surgery
Description: aorto-bifemoral bypass surgery (Leriche syndrom, elective AAA repair)
Study NCT02359188 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous vagal nerve stimulation
Description: 4 hours of transcutaneous vagal nerve stimulation
Study NCT01570348 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT03971487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychosis and cognitive assessments
Description: Administration of MINI, PANSS and Quality of Living scales
Study NCT03971487 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Psychosis and cognitive assessments
Description: Administration of MINI, PANSS and Quality of Living scales
Study NCT03971487 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical and neuro-cognitive evaluations
Description: Physical, neurological and cognitive evaluations.
Study NCT03971487 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical and neuro-cognitive evaluations
Description: Physical, neurological and cognitive evaluations.
Study NCT03971487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Safety labs and electrocardiogram
Description: Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
Study NCT03971487 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Safety labs and electrocardiogram
Description: Metabolic panel, CBC and differential, urinalysis, ECG, recreational drugs. CD19+ B-cell count.
Study NCT03971487 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab infusion
Description: Two IV infusions of 300 mg of ocrelizumab 2 weeks apart
Study NCT00775541 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: One IV infusion of 2 gm vitamin C
Study NCT02562482 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC-CHKVLP059-00-VP
Description: VRC-CHKVLP059-00-VP is a virus-like particle (VLP) vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins of the CHIKV (strain 37997).
Study NCT02562482 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: VRC-PBSPLA043-00-VP
Description: VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine.
Study NCT00517959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Conformal radiotherapy
Description: SCRT
Study NCT00517959 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Conventional radiotherapy
Study NCT03657108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Civasheet 60 Gy
Description: implantable proposed doses of Civasheet are 60 Gy
Study NCT01378143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI
Description: OCZ103-OS is given in combination with Chemotherapy each cycle
Study NCT03657108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Civasheet 75 Gy
Description: implantable proposed doses of Civasheet are 75 Gy
Study NCT03657108 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Adjuvant external beam radiation therapy
Description: 45 Gy in 25 fractions
Study NCT04688970 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT00003487 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Adenocarcinoma of the Esophagus will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study NCT00679913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard pancreatoduodenectomy
Description: Standard pancreatoduodenectomy
Study NCT00679913 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Extended pancreatoduodenectomy
Description: Extended pancreatoduodenectomy
Study NCT02044549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carbetocin
Description: Oxycontin analogue
Study NCT02044549 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Syntometrine
Description: Uterotonins
Study NCT00562770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valganciclovir
Description: 900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
Study NCT01890070 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chestnut
Description: Italian Organic Chestnut
Study NCT03569085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Description: The patient will receive Sevoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
Study NCT03569085 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoflurane
Description: The patient will receive isoflurane in incremental doses titrated to obtain end-tidal minimum alveolar concentration (MAC) of 0.5, 1.0, and 1.5.
Study NCT02776865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: suprascapular nerve block
Description: 4ml 2% xylocaine
Study NCT02776865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise
Study NCT02776865 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy
Description: patient received traditional physical therapy, including therapeutic exercise and stretch exercise
Study NCT00562770 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valacyclovir
Description: 500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
Study NCT03501537 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free gingival graft obtained from the palate and debridement of the peri-implant lesion
Description: granulation tissue debridement and grafting of a free gingival strip obtained from the palate
Study NCT01727687 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral training for crossing road
Description: behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
Study NCT00576641 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cells
Study NCT01032772 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Choices Plus
Description: Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
Study NCT01032772 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Information
Description: Participants are provided with informational materials about healthy lifestyle and local resources.
Study NCT02030314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: treatment of resistant hypertension in kidney transplant patients
Study NCT01095679 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Baclofen
Description: Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Study NCT03160625 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Rate Adaptive Pacing
Description: Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
Study NCT04607629 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Genolar® + Symbicort®
Description: The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
Study NCT01095679 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
Study NCT01405131 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: constituted powder for oral suspension 4 mg/mL single dose at 32 mg
Study NCT01405131 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylprednisolone
Description: tablets 32 mg single dose
Study NCT01374139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
Study NCT01374139 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bosutinib
Description: 4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
Study NCT04607629 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xolair® + Symbicort®
Description: The experimental drug dose and administration frequency were determined based on baseline IgE concentration (IU / ml) measured before treatment and current body weight (kg). Depending on the initial IgE concentration and body weight the recommended drug dose was from 75 to 600 mg once in 2 or 4 weeks. The experimental drug Genolar® and the reference drug Xolair® were administered subcutaneously for 26 weeks. Budesonide + formoterol inhalation (dosed powder for inhalation, each delivered dose contains 320 μg budesonide and formoterol fumarate dihydrate 9 μg)) 1 inhalation 2 times a day.
Study NCT01800786 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CPAP
Study NCT04232241 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation
Study NCT04232241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Stem Cell Transplantation
Description: Allogeneic Stem Cell Transplantation
Study NCT02206074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Beetroot
Study NCT02206074 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot
Study NCT00773942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Basic medication therapy management
Description: Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
Study NCT00773942 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced medication therapy management
Description: Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
Study NCT02932228 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ImPACT
Description: The ImPACT team offers the following services:~* An intensive intake process, including a home visit if deemed appropriate~* Frequent contact (in-person, telephone, or secure messaging) tailored to a patient's needs~* After-hours access to on-call team member in order to avoid unnecessary emergency care~* Optimization of chronic condition management using evidence-based protocols~* Navigation of transitions between hospital and home~* Coordination of specialty care, including contact with specialists when indicated~* Rapid response to signs of health status deterioration or other stressful events~* Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment
Study NCT01072266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB028060
Description: 10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
Study NCT02469779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Surveys
Description: At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
Study NCT02469779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Surveys
Description: At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
Study NCT02469779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ASPIRE Website
Description: Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
Study NCT02469779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASPIRE Text-Based Website
Description: Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
Study NCT01332643 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Preimplantation Genetic Diagnosis
Description: All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
Study NCT03988088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally.
Study NCT02109211 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intubation with Magill forceps
Study NCT02109211 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with altered Magill forceps
Study NCT03638609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intra Aortic Balloon Pump
Description: Intra Aortic Balloon Pump (IABP) is a circulatory mechanical support device, placed in descending aorta, distally from left subclavian artery and proximally from renal artery. IABP works with counterpulsation concept, synchronized with heart cycle. It is indicated as supportive therapy for patients undergoing revascularization, cardiogenic shock and mechanical complication.~Balloon dilatation during dyastolic phase increasing dyastolic pressure in aorta, improving coronary vascularization and myocardial oxygen supply. In systolic phase, the balloon deflates, reducing the left ventricle afterload hence decreasing myocardial oxygen demand.
Study NCT00532558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapaquistat acetate
Description: Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
Study NCT00532558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
Study NCT02469779 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Follow Up Survey
Description: Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
Study NCT02469779 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Follow Up Survey
Description: Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
Study NCT03231319 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca compartment block with IV-PCA
Description: 1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.